Bambusa Therapeutics ($BBTX) just filed for IPO. Clinical-stage biopharma developing half-life-extended bispecific antibodies for immunology & inflammation. Lead candidates BBT001 (Phase 1) in atopic

The financial picture: no revenue, no profitable operations, significant losses to date, and more losses expected ahead. Clinical-stage biotech means the income statement is a burn rate story until a drug works. Key risks: drug development is inherently uncertain and candidates may fail in trials. The company will need substantial additional capital and may not be able to raise it when needed. No revenue means no cushion if timelines slip. Use of proceeds: funding research and development activities. Underwriters: BofA Securities, Evercore ISI, UBS Investment Bank, Cantor. Founded May 2024, raised ~$15M seed in Sept 2024 and ~$90M Series A in Feb 2025 led by RA Capital. Bottom line: early-stage I&I play with strong Series A backing but zero revenue and a brutal biotech IPO backdrop—only five $50M+ biotechs went public in 2025 vs 18 in 2024. Later-stage, well-capitalized names are getting done. Bambusa is neither yet.

The financial picture: no revenue, no profitable operations, significant losses to date, and more losses expected ahead. Clinical-stage biotech means the income statement is a burn rate story until a